NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying

Published 26/01/2023, 14:18
© Reuters.  Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
IXIC
-
BMRA
-
JEWL
-

Benzinga - The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Eiger BioPharmaceuticals

  • The Trade: Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) Director Thomas J. Dietz bought a total of 50,000 shares at an average price of $1.43. To acquire these shares, it cost around $71.58 thousand.
  • What’s Happening: Eiger BioPharmaceuticals said on January 3, 2023, Sriram Ryali notified the company of resignation as Chief Financial Officer effective Jan. 20, 2023.
  • What Eiger BioPharmaceuticals Does: Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies.

Adamas One

  • The Trade: Adamas One Corp. (NASDAQ: JEWL) President and CEO John Grdina acquired a total of 40,000 shares at an average price of $2.67. The insider spent around $106.78 thousand to buy those shares.
  • What’s Happening: On the heels of its initial public offering, Adamas One reported $1.78 million in initial lab grown diamond sales for FY22.
  • What Adamas One Does: Adamas One Corp is a high-tech diamond company that uses its proprietary technology to produce high-quality, single-crystal diamonds and diamond materials through a CVD process, which it refers to as Diamond Technology.
Check This Out: 5 Most Expensive Energy Stocks You Should Worry About

Biomerica

  • The Trade: Biomerica, Inc. (NASDAQ: BMRA) CEO Zackary Irani acquired a total of 2,000 shares at an average price of $2.81. To acquire these shares, it cost around $5.62 thousand.
  • What’s Happening: Biomerica, last month, received Kingdom of Saudi Arabia Food And Drug Administration and Ministry of Health approval for colorectal screening and breast screening tests in Saudi Arabia and UAE.
  • What Biomerica Does: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.
Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.